Biopharmaceutical firm VBI Vaccines has expanded its collaboration with the Canadian government, with the latter contributing the remaining CAD$28 million from its CAD$56 million Strategic Innovation Fund. These funds will go towards developing VBI’s MLE platform, a next-generation version of its eVLP (enveloped virus-like particle) vaccine technology that allows for the mRNA coding of eVLPs.
The MLE platform has the potential to revolutionize particulate vaccines by generating strong B-cell and T-cell signals, as well as speeding up manufacturing timelines. The collaboration with the National Research Council of Canada will also result in the development of stable cell lines utilizing proprietary gene-editing techniques. These advancements will support late-stage clinical studies and contribute to future epidemic and pandemic preparedness.
VBI Vaccines is focused on treatments and preventative measures against diseases, relying on its innovative approach to virus-like particles, including a proprietary RNA-launched and enveloped VLP platform technologies. The company’s aim is to develop vaccine candidates that mimic the natural presentation of viruses to elicit powerful reactions from the human immune system.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
